Chemotherapy for the treatment of hormone-refractory prostate cancer.
OBJECTIVE
This review aims at analysing the published literature on chemotherapy for hormone-refractory prostate cancer (HRPC) to provide recommendations for the treatment of this important patient group.


METHODS
The information for this review was compiled using the PubMed and Medline databases and the Proceedings of the American Society of Clinical Oncology annual meetings to search for articles, abstracts and presentations up to 1 March 2007. Electronic early-release publications were also included. Only articles published in English were considered. The search terms included hormone-refractory prostate cancer, docetaxel, mitoxantrone, satraplatin, ixabepilone, cyclophosphamide, vinorelbine, atrasentan, calcitriol, bevacizumab and targeted therapies. Priority was given to studies in high impact factor journals when available.


CONCLUSIONS
Two recent trials (TAX 327 and SWOG 9916) have shown that docetaxel chemotherapy can significantly improve survival for HRPC. Docetaxel has become the standard of care for first-line chemotherapy for HRPC and has been approved for use in the United States and Europe. Many patients with HRPC will require second- and even third-line treatment upon progression and more data are required in this setting. It is likely that the future management of patients with HRPC will build on the success of docetaxel using a sequence of chemotherapy and targeted therapies to reduce the risk of death, prevent or improve disease-related symptoms and improve quality of life for this important condition.
Chowdhury
S
S
Medical Oncology, Guy's Hospital, London, UK. simonchowdhuryuk@yahoo.co.uk
Burbridge
S
S
Harper
P G
PG
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D016019:Survival Analysis; D016896:Treatment Outcome